Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSara NiyaziJPJavier Pinilla‐Ibarz

Discussion

Loading...

Member takes

Overview

Observational analysis revealed significant variation of cytotoxic CD57+ T cells in cutaneous T cell lymphoma patients, highlighting disease aggressiveness implications.

Key Points

  • Circulating CD57+ T cells significantly vary across disease states and aggressiveness in cutaneous T cell lymphoma.
  • In patients with Sézary syndrome, median CD4+ T cell levels were highest at diagnosis, suggesting their role in disease progression.
  • Analysis of peripheral blood cell subsets used multicolor flow cytometry to assess variations across clinical subgroups.
  • These findings support the notion that CD57+ subsets may play differential roles in pathogenesis versus immune response.

Cite This Study

Niyazi et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1e8https://doi.org/10.1182/blood-2025-3644
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Expanded CD4+CD57+ T-large granular lymphocytes: A diagnostic pitfall in blood staging of mycosis fungoides/Sézary syndrome2025
  2. 2Clinical and Prognostic Features of Erythrodermic Cutaneous T-Cell Lymphoma: A Retrospective Study of 35 Patients2025
  3. 3Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)2025
  4. 4Unraveling the role of chemokines in cutaneous T-cell lymphoma: expression levels at different stages2025
  5. 5High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy2025